---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-26-000016"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:36:33.097680+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma: DMC Recommends Continue Phase 2 Asthma/COPD Trials; Topline Data Mid-2026

## Summary
- DMC reviewed pre-specified interim efficacy of rademikibart (anti-IL-4Rα) in Phase 2 Seabreeze STAT trials; no sample size change.
- No treatment-related serious adverse events, no severe AEs, and no discontinuations due to AEs in either study.
- Topline data from both asthma and COPD studies expected in mid-2026; company plans FDA meeting for Phase 3.
- CEO Barry Quart: 'Rademikibart has potential to deliver differentiated efficacy and safety in acute exacerbations.'

## SEC filing metadata
- accession: 0001835268-26-000016
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000016/0001835268-26-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000016/cntb-20260423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-26-000016
- JSON: https://secwatch.observer/filing/0001835268-26-000016.json
- Plain text: https://secwatch.observer/filing/0001835268-26-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.